Search by Title Article Topic - Any -AdvocacyAnnual Scientific MeetingAwardsBoard Certification ReviewCertificationClinical DocumentClinical TrialsCoronavirusEarly CareerFellowshipFuture LeadersHeart Failure Awareness 365Heart Failure GuidelinesHF Research FoundationHFSA CommitteesHFSA Comprehensive Heart Failure ReviewHFSA Learning CenterIn The NewsIndustryJournal of Cardiac FailureLeadershipMembershipMentorshipNursingPartnersPatient ResourcePatient StoryPodcastsPresident's UpdatesPress ReleaseProfessional DevelopmentProvider EducationResearchSocial MediaStatementSubmissionsWomen in Heart Failure Article Type - Any -HFSA NewsIndustry NewsPatient NewsPractice News May 6 2022 | FARXIGA met primary endpoint in DELIVER Phase III trial, reducing risk of cardiovascular death or worsening heart failure in patients with preserved ejection fraction Industry News Industry Read More Apr 28 2022 | U.S. Food and Drug Administration Approves Camzyos™ (mavacamten) for the Treatment of Adults With Symptomatic New York Heart Association Class II-III Obstructive Hypertrophic Cardiomyopathy (HCM) to Improve Functional Capacity and Symptoms Industry News In The News Industry Read More Apr 26 2022 | Registration is Open for the HFSA Annual Scientific Meeting 2022 Read More Apr 22 2022 | Request for Proposals (RFP): Quality Improvement Grants to Support Development of Cardiac Amyloid Centers Industry News In The News Industry Read More Apr 14 2022 | New Episode of the Heart Failure Beat Discusses Challenges in Recruiting Trainees in the Field of Advanced Heart Failure HFSA News Podcasts Provider Education Read More Pagination First page « First Previous page ‹ Previous … Page 62 Page 63 Page 64 Page 65 Current page 66 Page 67 Page 68 Page 69 Page 70 … Next page Next › Last page Last »
May 6 2022 | FARXIGA met primary endpoint in DELIVER Phase III trial, reducing risk of cardiovascular death or worsening heart failure in patients with preserved ejection fraction Industry News Industry Read More
Apr 28 2022 | U.S. Food and Drug Administration Approves Camzyos™ (mavacamten) for the Treatment of Adults With Symptomatic New York Heart Association Class II-III Obstructive Hypertrophic Cardiomyopathy (HCM) to Improve Functional Capacity and Symptoms Industry News In The News Industry Read More
Apr 22 2022 | Request for Proposals (RFP): Quality Improvement Grants to Support Development of Cardiac Amyloid Centers Industry News In The News Industry Read More
Apr 14 2022 | New Episode of the Heart Failure Beat Discusses Challenges in Recruiting Trainees in the Field of Advanced Heart Failure HFSA News Podcasts Provider Education Read More
